BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase HYALOFAST®, a biodegradable, HA-based cartilage repair scaffold, at the 14th World Congress of the of the International Cartilage Repair Society (ICRS). The ICRS World Congress, which is being held in Macau, China during April 9-12, 2018, is the world’s largest gathering of scientists, clinicians and industry participants focused on clinical cartilage repair and basic cartilage research.
“HYALOFAST represents a major advancement in the treatment of cartilage injuries and defects, evidenced by the positive reception it has received from physicians across 15 global markets,” said Joseph Darling, President and CEO, Anika Therapeutics. “The ICRS World Congress is the ideal venue to showcase the significant advantages HYALOFAST offers over invasive open surgical techniques and traditional scaffolds, to the largest gathering of cartilage repair specialists from around the world. At this year’s meeting, we’ve developed a robust educational agenda featuring world-renowned thought-leaders with HYALOFAST expertise sharing their technical know-how and providing hands-on, guided training sessions with our custom-built HYALOFAST Virtual Surgical Simulator. We believe that peer-to-peer education and technical training is central to prompting the HYALOFAST trial, which we hope will increase commercial adoption.”
HYALOFAST is a non-woven, single-step, off-the-shelf, biodegradable HA-based scaffold for hyaline-like cartilage regeneration to treat cartilage injuries and defects. HYALOFAST is commercially available in over 15 countries and has been used to successfully treat more than 14,000 patients internationally, and with strong five-year patient follow-up data. HYALOFAST is pending regulatory submission in the United States and its FastTRACK Phase III trial is currently enrolling patients across the U.S. and Europe.
Company-Sponsored Lunch Symposium
Location: Room Almaty 3, Sheraton Grand Macau Hotel
Tuesday, April 10, 2018
12:30 – 13:30 Almaty 3 Room, Lunch Symposium: HYALOFAST One-step
Procedure: Best Practice and New Evidence in Cartilage Repair.
Moderator: Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy
Speakers: Dr. Bogusław Sadlik, St. Luke Hospital – Bielsko Biala – Poland, Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy, Prof. Stephan Nehrer, Danube University, Krems – Austria
Company-Sponsored Physician Education Availability
Location: Anika Booth #16, Sheraton Grand Macau Hotel
Monday, April 9, 2018
- 15:15 – 16:15 Dr. Tho Kam San, Mount Alvernia and Gleneagles Hospitals – Singapore, will be available at the booth for guided training sessions with the HYALOFAST Virtual Surgical Simulator.
Tuesday, April 10, 2018
- 11:00 – 12:00 Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy, will be available at the booth for guided training sessions with the HYALOFAST Virtual Simulator.
Wednesday, April 11, 2018
- 13:00 – 14:00 Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy, will be available at the booth for guided training sessions with the HYALOFAST Virtual Simulator.
The ICRS (International Cartilage Repair Society) is the main forum for international collaboration in cartilaginous tissue research that brings together basic scientists, clinical researchers, physicians and members of industry, engaged or interested in the field of articular biology, its genetic basis and regenerative medicine. It provides continuing education and training to physicians and scientists with an active interest in the prevention and treatment of joint disease to improve patient care through regenerative medicine approaches.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.
The statements made in the second and third paragraphs of this press release, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to HYALOFAST’s impact and its regulatory trajectory. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including (i) the Company’s ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all, obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, or timely file and receive FDA or other regulatory approvals or clearances of its products, or that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (ii) the Company’s research and product development efforts, and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (iii) the cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations and production planning; (iv) the strength of the economies in which the Company operate or will be operating, as well as the political stability of any of those geographic areas; (v) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (vi) the Company’s ability to successfully commercialize its products, in the U.S. and abroad; (vii) the Company’s ability to provide an adequate and timely supply of its products to its customers; (viii) the Company’s ability to continue to successfully manage Anika Therapeutics S.r.l.’s business; and (ix) the Company’s ability to achieve its growth targets.